Idexx Laboratories (IDXX) Net Income towards Common Stockholders (2009 - 2026)

Idexx Laboratories has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $338.4 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 15.11% year-over-year to $338.4 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 15.62% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 19.33% from the prior year.
• Net Income towards Common Stockholders was $338.4 million for Q2 2026 at Idexx Laboratories, up from $278.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $338.4 million in Q2 2026, with the low at $132.0 million in Q2 2022.
• Average Net Income towards Common Stockholders over 5 years is $227.1 million, with a median of $220.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders tumbled 34.86% in 2022, then jumped 69.9% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at $172.2 million in 2022, then grew by 12.96% to $194.5 million in 2023, then rose by 11.12% to $216.1 million in 2024, then grew by 14.82% to $248.2 million in 2025, then soared by 36.35% to $338.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $338.4 million (Q2 2026), $278.4 million (Q1 2026), and $248.2 million (Q4 2025), per Business Quant data.